Genflow Biosciences plc

LSE:GENF Stock Report

Market Cap: UK£6.1m

Genflow Biosciences Valuation

Is GENF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GENF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GENF's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GENF's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GENF?

Key metric: As GENF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GENF. This is calculated by dividing GENF's market cap by their current revenue.
What is GENF's PS Ratio?
PS Ratio10.2x
SalesUK£598.04k
Market CapUK£6.12m

Price to Sales Ratio vs Peers

How does GENF's PS Ratio compare to its peers?

The above table shows the PS ratio for GENF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.7x
APTA Aptamer Group
7.6xn/aUK£6.5m
VRCI Verici Dx
2.4x78.8%UK£8.2m
PBX ProBiotix Health
4.8xn/aUK£10.3m
BSFA BSF Enterprise
44.2xn/aUK£3.0m
GENF Genflow Biosciences
10.2xn/aUK£6.1m

Price-To-Sales vs Peers: GENF is good value based on its Price-To-Sales Ratio (10.2x) compared to the peer average (14.7x).

Price to Sales Ratio vs Industry

How does GENF's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.5x21.0%US$553.81m
TRX Tissue Regenix Group
1.6x15.1%US$50.82m
PBX ProBiotix Health
4.8xn/aUS$12.87m
GENF 10.2xIndustry Avg. 8.0xNo. of Companies7PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GENF is expensive based on its Price-To-Sales Ratio (10.2x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is GENF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GENF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GENF's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€821.0m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

hVIVO

UK£155.8m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%